RE:RE:TD...it's the uncertainty around the 2018 fee schedule and a lack of movement on the acquisition front that has created a lack of conviction for any significant investment by institutions...the price may be attractive at the current level however only when there is a catalyst, a significant acquisition that will give direction, will the sp recover...
TD's 3rd point "expansion opportunities within CRH's core anesthesiology market."
has to be realized...